Key Investor Signals
Two-hospital study showed RF sensing tracked heart and breathing changes.
At HFA 2026, PrecorDx presented patient data showing its RF-sensing signal tracked changes in stroke volume and respiratory motion during catheter-lab procedures and haemodialysis.
€250,000 NWO grant and 2026 Health~Holland consortium funding
PrecorDx received a €250,000 NWO Take-off phase 2 grant and later secured additional Health~Holland funding through the 2026 INFORM-HF consortium.
Granted patents protect the core sensing technology
The core sensing technology is protected by granted patents in Australia and Japan, with a U.S. patent application filed.
Other Positive Signals
- Won the 2022 Health~Holland Venture Challenge, receiving a €25,000 prize.
- Hired Iris Huijben, PhD, in 2026 to lead signal processing and algorithm development, bringing experience from NXP Semiconductors, Meta and Qualcomm.
Team
Jaap de Bruin
Co-founder and CEO
- Led the FIRST fund at BioGeneration Ventures from 2023 to 2025, backing Dutch cardiovascular and regenerative-medicine spin-outs.
- Previously managed the Utrecht Health Seed Fund and worked in Philips Healthcare's Image Guided Therapy and corporate incubator.
- Served as interim Managing Director of UtrechtInc from October 2025 to June 2026.
Bart Steensma
Co-founder and board member
- Assistant Professor in UMC Utrecht's Computational Imaging Group, leading research on wearable technology for cardiovascular diagnosis and prevention.
- Co-inventor of the RF-sensing method behind PrecorDx and a named inventor on the company’s core patent family.
- PhD in radio-frequency antenna design for high-field MRI, following an MSc in biomedical engineering.
Nico van den Berg
Co-founder and scientific advisor
- Professor of Computational Imaging at UMC Utrecht and head of the Computational Imaging research group.
- More than 20 years at UMC Utrecht, progressing from research physicist to full professor in MR physics and computational imaging.
- Co-inventor of the RF-sensing patent family and a scientific leader in translating imaging technologies into clinical research.
Maarten Kolk
Co-founder and Chief Medical Officer
- Physician and postdoctoral researcher in cardiology at Amsterdam UMC, with clinical work as a cardiology resident.
- Completed a PhD in artificial intelligence for cardiac electrophysiology at Amsterdam UMC.
- Researched remote arrhythmia monitoring in the HartWacht programme, giving him direct experience with home cardiac monitoring.
- Co-leads the 2026 INFORM-HF consortium with heart-failure investigators at UMCG and UMC Utrecht.
Product
PrecorDx is developing a wearable device that measures tiny changes in reflected radio waves as the heart and lungs move. The current prototype is being tested in cardiovascular patients and compared with established clinical measurements.
Non-invasive cardiac monitoring with RF sensing
A small chest-worn antenna sends low-power radio waves into the body and measures the reflected signal. The pattern changes with cardiac and respiratory motion, allowing the system to detect physiological movement without an implanted sensor.
Comparing signals with clinical measures
The AIM-HF research program compares RF-sensing features with echocardiography, MRI and catheter measurements to validate the wearable signal against established measures of cardiac function and pressure.
Wearable hardware for repeated monitoring
The prototype combines the chest antenna with a miniature network analyser that can be worn on the body. This architecture is designed for repeated measurements outside scanner-based workflows without an implanted sensor.
Market Overview
Heart failure affected an estimated 56.1 million people worldwide in 2023 and carries a large recurring care burden because it can worsen before symptoms become obvious. Frequent monitoring could help clinicians adjust therapy earlier, but echocardiography and MRI are hospital-based, while implantable pressure sensors require a procedure.
Remote cardiac monitoring is already clinically and commercially established, including implantable systems such as CardioMEMS that enable patients to transmit cardiovascular data from home. PrecorDx is targeting a non-invasive route to repeated cardiac-function monitoring outside the hospital.
Estimated global prevalence in 2023 from the Global Burden of Disease 2023 study.
Estimated direct and indirect costs across 179 countries in 2021.
A 2026 contemporary review reports roughly 30% one-year rehospitalisation after heart-failure care.
Estimated 2025 market value, projected to reach $15.82B by 2034.
Comparable Outcomes
Preventice Solutions
Preventice Solutions developed wearable cardiac monitors and remote services that detected irregular heart rhythms outside hospitals. Boston Scientific acquired Preventice Solutions in March 2021 for up to $1.225B.
CardioMEMS
CardioMEMS developed an implantable pulmonary-artery pressure sensor that let heart failure patients take daily readings at home and transmit them to clinicians. St. Jude Medical acquired CardioMEMS in May 2014 in a transaction valued at more than $450 million.
Interested in More Startups Like PrecorDx?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.